Sign in
CompletedNo phase

Satisfaction of Patients With Erectile Dysfunction With the Use of Sildenafil Oral Suspension Compared to Orodispersible Tablets

Key facts

Who runs it
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
55 people enrolled
Started
1 Jun 2026
Ended
31 Aug 2026
Type of study
Observational
Treatments tested
  • Sildenafil Oral Suspension Compared to Orodispersible Tablets
Record updated
6 October 2026

Who can take part

Age
18 years to 75 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age 18-75
  • Male
  • Sexually active (at least 2 sexual encounters per week)
  • IIEF-EF between 11 and 25 at baseline

Who cannot take part

  • previous pelvic surgery
  • concomitant use of other ED therapies
  • conical therapy with nitrates or other contraindicated drugs in combination with sildenafil
  • patients who have lost vision in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION), whether or not this event was related to previous use of a phosphodiesterase type 5 (PDE5) inhibitor
  • patients treated with guanylate cyclase stimulants, such as riociguat
  • hypersensitivity to the active ingredient
  • patients for whom sexual activity is not recommended (e.g. patients with serious cardiovascular disorders, such as unstable angina or severe heart failure)
  • patients with severe hepatic impairment, hypotension (blood pressure <90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal diseases, such as retinitis pigmentosa
  • hypogonadism (total testosterone < 3.5 ng/mL)
  • ED on a neurogenic basis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this observational retrospective study is to to evaluate treatment satisfaction with sildenafil oral suspension in patients with mild-to-moderate ED who were previously taking orodispersible sildenafil.

Read full original descriptionShow less

The secondary objective is to evaluate the efficacy and side effects of therapy with sildenafil oral suspension compared to orodispersible sildenafil.

Patients who took sildenafil orodispersible 50 mg for 3 months and subsequently took sildenafil oral suspension for another 3 months will be enrolled.

The group in the trial

  • group 1

    Treatment: Sildenafil Oral Suspension Compared to Orodispersible Tablets

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
6 October 2026